Literature DB >> 16643953

Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies.

Maria Pia Amato1, Valentina Zipoli, Emilio Portaccio.   

Abstract

Prevalence estimates of cognitive impairment in multiple sclerosis (MS) range from 40% to 65%, depending on the research setting. Cognitive dysfunction virtually encompasses all the disease stages and types of clinical course, although it is generally less frequent in relapsing-remitting (RR) patients compared with secondary progressive (SP) patients, and tends to be less frequent in primary progressive (PP) patients. Moreover, it causes role limitations in work and social life, independently of the degree of physical disability. Relatively little is known about the evolution of cognitive impairment in MS, particularly starting from the early stages of the disease. Controlled studies, however, have clearly shown that cognitive deterioration tends to progress over time. Among clinical predictors, incipient cognitive decline seems to be the major risk factor for further deterioration in the short-term. In the long-term, the likelihood increases that also patients with initial cognitive preservation may deteriorate. As for magnetic resonance imaging (MRI), there are consistent, albeit moderate, correlations between the progression of cognitive impairment and increasing brain lesion load and brain atrophy. The aim of this paper is to provide a review of existing cross-sectional and longitudinal studies on cognitive deterioration in MS.

Entities:  

Mesh:

Year:  2006        PMID: 16643953     DOI: 10.1016/j.jns.2005.08.019

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  125 in total

1.  Validation of the Comprehensive International Classification of Functioning, Disability, and Health Core Set for multiple sclerosis from the perspective of physicians.

Authors:  Stephanie Berno; Michaela Coenen; Andreas Leib; Alarcos Cieza; Jürg Kesselring
Journal:  J Neurol       Date:  2012-01-24       Impact factor: 4.849

2.  Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study.

Authors:  Francesco Patti; Maria Pia Amato; Stefano Bastianello; Luisa Caniatti; Elisabetta Di Monte; Fausto Lijoi; Benedetta Goretti; Silvia Messina; Orietta Picconi; Maria Rosalia Tola; Maria Trojano
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

3.  Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment.

Authors:  Ida S Haussleiter; Martin Brüne; Georg Juckel
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

4.  Youth and environmental enrichment generate serum exosomes containing miR-219 that promote CNS myelination.

Authors:  Aya D Pusic; Richard P Kraig
Journal:  Glia       Date:  2013-12-04       Impact factor: 7.452

5.  Prevalence and incidence of cognitive impairment in multiple sclerosis: a population-based survey in Catania, Sicily.

Authors:  Francesco Patti; Alessandra Nicoletti; Silvia Messina; Elisa Bruno; Salvatore Lo Fermo; Graziella Quattrocchi; Clara Grazia Chisari; Davide Maimone; Sabina Cilia; Mario Zappia
Journal:  J Neurol       Date:  2015-02-07       Impact factor: 4.849

6.  Multiple sclerosis with predominant, severe cognitive impairment.

Authors:  Nathan P Staff; Claudia F Lucchinetti; B Mark Keegan
Journal:  Arch Neurol       Date:  2009-09

7.  Functional MR imaging correlates of neuropsychological impairment in primary-progressive multiple sclerosis.

Authors:  M A Rocca; G Riccitelli; M Rodegher; A Ceccarelli; A Falini; M Falautano; A Meani; G Comi; Massimo Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

8.  Ecological Momentary Assessment of Pain, Fatigue, Depressive, and Cognitive Symptoms Reveals Significant Daily Variability in Multiple Sclerosis.

Authors:  Anna L Kratz; Susan L Murphy; Tiffany J Braley
Journal:  Arch Phys Med Rehabil       Date:  2017-07-18       Impact factor: 3.966

Review 9.  Grey matter lesions in MS: from histology to clinical implications.

Authors:  Massimiliano Calabrese; Alice Favaretto; Valeria Martini; Paolo Gallo
Journal:  Prion       Date:  2012-10-23       Impact factor: 3.931

Review 10.  Soluble HLA-G: Are they clinically relevant?

Authors:  Vito Pistoia; Fabio Morandi; Xinhui Wang; Soldano Ferrone
Journal:  Semin Cancer Biol       Date:  2007-07-31       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.